Published in J Clin Oncol on October 25, 2010
5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncol Lett (2012) 0.94
Another step toward the cure of metastatic renal cell carcinoma? J Clin Oncol (2010) 0.91
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol (2006) 2.34
Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res (2004) 2.23
Prognostic impact of young age on stage IV prostate cancer treated with primary androgen deprivation therapy. Int J Urol (2014) 2.21
Inhibition of mTORC2 but not mTORC1 up-regulates E-cadherin expression and inhibits cell motility by blocking HIF-2α expression in human renal cell carcinoma. J Urol (2012) 2.08
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol (2005) 2.08
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Feasibility of insertion/implantation of 2.0-mm-diameter gold internal fiducial markers for precise setup and real-time tumor tracking in radiotherapy. Int J Radiat Oncol Biol Phys (2003) 2.00
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol (2011) 1.84
Variation in course of cavernous nerve with special reference to details of topographic relationships near prostatic apex: histologic study using male cadavers. Urology (2005) 1.80
Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol (2007) 1.77
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res (2005) 1.66
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Retroperitoneal fibrosis: a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol (2009) 1.63
Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys (2002) 1.63
Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int (2012) 1.61
Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res (2007) 1.61
Prevalence of human papillomavirus infection in the urinary tract of men with urethritis. Int J Urol (2010) 1.58
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol (2007) 1.58
Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 1.56
An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol (2004) 1.53
The role of lymph-node dissection in the treatment of upper urinary tract cancer: a multi-institutional study. BJU Int (2008) 1.53
Effect of varicocelectomy on patients with unobstructive azoospermia and severe oligospermia. BJU Int (2007) 1.52
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol (2009) 1.51
Baseline erectile function alters the cavernous nerve quantity and distribution around the prostate. J Urol (2010) 1.49
Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. J Urol (2007) 1.49
Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol (2010) 1.49
Changes in dopaminergic and glutamatergic excitatory mechanisms of micturition reflex after middle cerebral artery occlusion in conscious rats. Exp Neurol (2002) 1.48
National institutes of Health Chronic Prostatitis Symptom Index for Japanese men. Urology (2002) 1.48
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci (2011) 1.46
Pattern of intravesical recurrence after surgical treatment for urothelial cancer of the upper urinary tract: a single institutional retrospective long-term follow-up study. Int J Urol (2010) 1.45
Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. Int J Urol (2013) 1.44
Long-term changes in renal function outcomes following radical cystectomy and urinary diversion. Int J Clin Oncol (2014) 1.44
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol (2012) 1.44
Renal angiomyolipoma with minimal fat. Int J Clin Oncol (2002) 1.44
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
RENAL nephrometry score is a predictive factor for the annual growth rate of renal mass. Int J Urol (2014) 1.43
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol (2009) 1.42
α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol (2012) 1.42
Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. Int J Urol (2011) 1.42
Comparison of testosterone fractions between Framingham Heart Study participants and Japanese participants. Int J Urol (2014) 1.42
Cavernous nerve reconstruction with a biodegradable conduit graft and collagen sponge in the rat. J Urol (2005) 1.41
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol (2008) 1.41
Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol (2012) 1.40
New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts. Transplantation (2015) 1.40
The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A). Jpn J Clin Oncol (2002) 1.40
Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol (2003) 1.40
Tissue elasticity imaging for diagnosis of prostate cancer: a preliminary report. Int J Urol (2006) 1.40
Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases. Urology (2009) 1.39
Impact of visceral fat ratio on sleep-related erection: a retrospective study of elderly patients. Int J Urol (2014) 1.39
Cancer death from non-muscle invasive bladder cancer: report of the Japanese Urological Association of data from the 1999-2001 registry in Japan. Int J Urol (2010) 1.39
Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl (2015) 1.39
Treatment of brain metastases from renal cell carcinoma with sunitinib and radiotherapy: our experience and review of the literature. Int J Urol (2011) 1.39
The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res (2004) 1.38
Risk factors for the development of well leg compartment syndrome after sex reassignment surgery in patients with gender identity disorder. Int J Urol (2013) 1.38
A novel Y chromosome microdeletion with the loss of an endogenous retrovirus related, testis specific transcript in AZFb region. J Urol (2011) 1.38
Conventional versus microdissection testicular sperm extraction for nonobstructive azoospermia. J Urol (2002) 1.36
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int (2006) 1.36
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
Local recurrence after radical cystectomy for invasive bladder cancer: an analysis of predictive factors. Urology (2004) 1.33
Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int J Urol (2006) 1.30
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28
Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci (2007) 1.28
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Prostate (2007) 1.27
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26
Prostate Cancer Working Group report. Jpn J Clin Oncol (2010) 1.25
Management of renal angiomyolipomas associated with tuberous sclerosis complex. J Urol (2004) 1.25
Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res (2003) 1.24
NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res (2004) 1.24
Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol (2010) 1.24
Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med (2013) 1.23
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol (2004) 1.22
Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int (2002) 1.20
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer (2007) 1.19
Bilateral epididymal sarcoidosis presenting without radiographic evidence of intrathoracic lesion: Review of sarcoidosis involving the male reproductive tract. Int J Urol (2004) 1.19
Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol (2010) 1.18
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol (2010) 1.18